基因检测提高了乳腺癌的精确诊断和治疗
Tinglin Yang1, Wenhui Li1, Tao Huang1
1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
International journal of molecular sciences
|December 9, 2023
概括
基因检测通过使精确的诊断和治疗成为可能,推动了乳腺癌的治疗. 来自基因表达和突变的分子洞察力指导早期和转移性乳腺癌的治疗选择.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 乳腺癌是一种复杂,异质的恶性瘤.
- 传统的诊断方法对于精确的管理是不够的.
- 了解分子水平对于个性化治疗至关重要.
研究的目的:
- 审查基因测试在乳腺癌管理中的作用.
- 总结早期和转移性疾病中的应用.
- 讨论基因测试的好处和挑战.
主要方法:
- 关于乳腺癌遗传检测的当前文献的综述.
- 对基因表达特征和基因突变的分析.
- 多基因测试 (MGA) 和向基因测试的评估.
主要成果:
- 基因检测有助于准确的诊断和治疗选择.
- MGAs有助于辅助治疗决策和早期乳腺癌的预后预测.
- 特定基因测试可以确定转移性乳腺癌的有效抗瘤剂.
结论:
- 基因检测是现代乳腺癌精准医学不可或缺的一部分.
- 它在量身定制治疗和预测结果方面提供了显著的优势.
- 目前正在进行的研究解决了进一步优化其使用的挑战.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


